2m 2m 2m 2m 2m 2m 2m
Galmed Pharmaceu (GLMD)
NASDAQ
$0.70+$0.005 (+0.71%)
Price as of Jun 03, 2026 6:25 PM EDT- $8.4MMarket Cap
- -53.30%1-Year Change
- BiotechnologyIndustry
Galmed Pharmaceu (GLMD)
$0.70+$0.005 (+0.71%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -4.9M +63.61% | -3.0M -16.53% | -3.6M -72.54% | -13.0M -52.26% | |
Depreciation and Amortization Expense | N/A N/A | 83,000 +167.74% | 31,000 -11.43% | 35,000 -16.67% | |
Total Operating Expenses | 8.5M +35.55% | 6.3M -16.20% | 7.5M -57.55% | 17.7M -46.32% | |
Operating Profit | 7.5M 0.00% | 7.5M +208.75% | -6.9M -61.31% | -17.9M -44.97% | |
Interest Income | -914,000 +81.71% | -503,000 +34.13% | -375,000 +26.26% | -297,000 -171.74% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | -914,000 +81.71% | -503,000 +34.13% | -375,000 +26.26% | -297,000 -171.74% | |
Total Nonoperating Income and Expense | 741,000 +43.60% | 516,000 -11.03% | 580,000 +369.77% | -215,000 -151.93% | |
Income before Taxes | 7.5M 0.00% | 7.5M +208.75% | -6.9M -61.31% | -17.9M -44.97% | |
Income Taxes | 0 N/A | N/A N/A | 16,000 N/A | N/A N/A | |
Extraordinary Items | N/A N/A | 1.1M N/A | N/A N/A | N/A N/A | |
Net Income | 6.9M -13.75% | 8.0M +215.74% | -6.9M -61.31% | -17.9M -44.97% | |
Net Income from Continuing Operations Applicable to Common | 7.5M 0.00% | 7.5M +208.75% | -6.9M -61.31% | -17.9M -44.97% | |
Basic EPS and Net Income | 2.39 -70.42% | 8.08 +223.20% | 2.50 +252.11% | 0.71 -46.21% | |
Diluted EPS and Net Income | 2.39 -70.42% | 8.08 +223.20% | 2.50 +252.11% | 0.71 -46.21% | |
Basic Weighted Average Shares | 4.3M +363.17% | 930,822 -66.39% | 2.8M -88.98% | 25.1M +2.22% | |
Diluted Weighted Average Shares | 4.3M +363.17% | 930,822 -66.39% | 2.8M -88.98% | 25.1M +2.22% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 4.0M -14.34% | 4.7M +62.60% | 2.9M +41.91% | 2.0M -30.10% | |
Short-Term Investments | 7.0M -2.20% | 7.2M -4.58% | 7.5M -36.04% | 11.8M -63.14% | |
Cash and Cash Equivalents and Short-Term Investments | 11.0M -6.97% | 11.8M +13.92% | 10.4M -24.64% | 13.8M -60.40% | |
Total Current Assets | 18.6M +15.52% | 16.1M +21.79% | 13.2M -10.09% | 14.7M -59.16% | |
Accumulated Depreciation | N/A N/A | 1.1M +8.24% | 1.0M +3.14% | 988,000 +3.24% | |
Property and Plant and Equipment and Net | N/A N/A | 737,000 +787.95% | 83,000 -27.19% | 114,000 -21.38% | |
Total Long-Term Assets | N/A N/A | 2.4M -29.91% | 3.4M +84.54% | 1.8M +233.39% | |
Total Assets | 18.6M +0.69% | 18.5M +11.25% | 16.6M +0.41% | 16.6M -54.76% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 2.8M +30.92% | 2.2M -20.98% | 2.8M -11.12% | 3.1M -47.37% | |
Total Long-Term Debt | N/A N/A | 257,000 N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | N/A N/A | 1.7M +165.13% | 628,000 +1,327.27% | 44,000 -80.79% | |
Total Liabilities | 2.8M +30.92% | 2.2M -20.98% | 2.8M -12.36% | 3.1M -48.62% | |
Retained Earnings | -210.8M +5.14% | -200.5M +3.90% | -193.0M +3.72% | -186.0M +10.62% | |
Total Stockholders Equity | 15.8M -3.34% | 16.3M +17.64% | 13.9M +3.40% | 13.4M -55.99% | |
Total Shares Outstanding | 6.6M +295.31% | 1.7M -67.00% | 5.0M -79.98% | 25.2M +0.46% | |
Cash Flow | |||||
Cash from Operating Activities | -6.3M +7.40% | -5.9M -4.19% | -6.1M -66.83% | -18.5M -43.75% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | 4,000 -63.64% | |
Cash from Investing Activities | -3.4M +203.78% | -1.1M -238.87% | 800,000 -95.44% | 17.6M +53.23% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 9.0M +2.73% | 8.8M +42.05% | 6.2M +8,735.71% | 70,000 -99.60% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | 37.17% -18.39% | 45.55% +209.35% | -41.65% -38.03% | -67.21% -7.90% | |
Return on Equity | 42.98% -18.86% | 52.97% +204.61% | -50.63% -37.76% | -81.36% -6.47% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 6.55 -11.76% | 7.42 +54.13% | 4.81 +1.16% | 4.76 -22.40% | |
Cash Ratio | 1.40 -34.57% | 2.14 +105.77% | 1.04 +59.67% | 0.65 +32.82% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow